1. 50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. (December 2022) Authors: Quixabeira, D.C.A.; Pakola, S.; Jirovec, E.; Basnet, S.; Santos, J.M.; Kudling, T.; Clubb, J.; Haybout, L.; Arias, V.; Grönberg-Vähä-Koskela, S.; Havunen, R.; Cervera-Carrascon, V.; Pasanen, A.; Tapper, J.; Kanerva, A.; Hemminki, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Muscles of the trunk and pelvis are responsive to testosterone administration: data from testosterone dose–response study in young healthy men. (26th December 2017) Authors: Tapper, J.; Arver, S.; Pencina, K. M.; Martling, A.; Blomqvist, L.; Buchli, C.; Li, Z.; Gagliano‐Jucá, T.; Travison, T. G.; Huang, G.; Storer, T. W.; Bhasin, S.; Basaria, S. Journal: Andrology Issue: Volume 6:Number 1(2018) Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗